Approvals/NMPA/Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation

Approved

化学药品

Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation

LABORATOIRE GLAXOSMITHKLINE🇨🇳 National Medical Products Administration

Approval Id: 7MazXbYvV2M
Approval Number: H20150325
Generic Name: 沙美特罗替卡松吸入粉雾剂
Generic Name En: Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation
Trade Name: 舒利迭
Brand Name: 舒利迭
Drug Type: 化学药品
Dosage Form: 吸入粉雾剂
Strength: 每泡含昔萘酸沙美特罗50μg（按C₂₅H₃₇NO₄计）与丙酸氟替卡松500μg，递送剂量为昔萘酸沙美特罗47µg（按C₂₅H₃₇NO₄计）与丙酸氟替卡松460µg
Reg Date: 2020-02-04
Expired Date: 2025-02-03
Company Name: LABORATOIRE GLAXOSMITHKLINE
Company Address: 23 rue Francois Jacob, 92500 RUEIL-MALMAISON, FRANCE
Production Company Name: GLAXO WELLCOME PRODUCTION
Production Company Address: Zone Industrielle n° 2, 23 rue Lavoisier, 27000 Evreux, France
Company Detail Path: /organization/laboratoire-glaxosmithkline
Production Company Detail Path: /organization/glaxo-wellcome-production

Approved

Agency

NMPA

Country

🇨🇳

Approval Date

Feb 4, 2020

Approval ID

7MazXbYvV2M

Type

化学药品